Cheaper Ozempic in Canada will change weight care and body expectations
Generic semaglutide will expand access to effective metabolic treatment, but lower prices also risk fuelling cosmetic use, stigma and unrealistic expectations about bodies.
Copy link
By Torontoer Staff
Canada is on the brink of widespread access to generic semaglutide, the drug behind brand names such as Ozempic and Wegovy. Lower prices will make a proven metabolic therapy far more available, but they will also reshape public expectations about weight, who should take medication and what counts as health.
Public health data show why the drug matters. Statistics Canada reports 68 per cent of adults were overweight or obese in 2022 to 2024, with half of adults exhibiting abdominal obesity. Experts say the pandemic accelerated a long-term rise in excess weight, and many clinicians view semaglutide as an important tool for reducing related chronic illness.
A turning point for treatment
Semaglutide has been prescribed for diabetes and, at higher doses, for weight management and some cardiovascular conditions. A patent lapse in Canada opened the door to generics, which could reduce the cost of a four-week pen from roughly $223 to as little as $78. That price drop will change who can consider long-term therapy for obesity and metabolic disease.
Clinicians cite benefits beyond weight loss. Trials have shown semaglutide can lower cardiovascular risk and improve markers of metabolic health, even for some patients who do not lose much weight. For people with obesity-related illness, affordable access could reduce the burden on the health-care system.
Who benefits, and who may not
Semaglutide is effective for many, but not all. In major trials, roughly 14 per cent of participants lost little to no weight. Side effects such as nausea, vomiting and gastrointestinal distress are common. Rapid weight loss may cause muscle loss for some patients, and most people need ongoing treatment to maintain weight reductions.
Obesity is a chronic, relapsing, unrelenting, recurring disease that absolutely deserves the same status as diabetes and hypertension and coronary disease.
Stephen Glazer, medical director, Humber River Hospital
Access remains uneven. Provincial drug plans generally cover semaglutide for diabetes, but not for weight loss. Physicians have discretion to prescribe off-label, while direct-to-consumer telehealth services have already created a market for private, paid access. Generics will reduce price barriers, but public coverage decisions will still shape who can afford sustained treatment.
Culture, gender and body image
Lower costs raise a cultural question. Recent prescription patterns show many more women than men are taking weight-loss drugs, highlighting how social pressure, job and dating markets, and body policing shape demand. Advocates worry that cheaper drugs will amplify the trend toward cosmetic use, and increase stigma for people who cannot or choose not to take them.
People are worried it’s going to double or triple people’s experience of stigma.
Deborah McPhail, health sociologist, University of Manitoba
Small studies link willingness to try GLP-1 drugs to greater body shame, disordered eating behaviours and anti-fat bias. Other research finds people judge those who use medication to lose weight more harshly than people who lose the same amount through diet and exercise alone. Those perceptions mirror long-standing bias against all medical routes to weight loss, including surgery.
Practical considerations for patients
- Benefits: improved blood-sugar control, reduced risk markers for cardiovascular and liver disease, and significant weight loss for many patients.
- Limitations: common gastrointestinal side effects, variable individual response, potential muscle loss with rapid weight reduction, and need for long-term use to maintain results.
- Access and cost: generics will lower prices, but public coverage varies by province and by indication.
- Clinical assessment: waist circumference or body composition is more useful than body mass index to evaluate health risk related to fat distribution.
Clinicians advise careful assessment. Some specialists urge reserving GLP-1 therapy for patients with clinical obesity or overweight with comorbidities, rather than for purely cosmetic goals. Others note the importance of treating obesity as a chronic disease shaped by biology, genetics and environment.
Weight doesn’t tell us anything about fat.
Katherine Morrison, co-director, Centre for Metabolism, Obesity and Diabetes Research, McMaster University
For patients who do start therapy, expect a process: dose titration to reduce side effects, monitoring for metabolic improvements, and discussion of long-term plans, including the possibility that stopping medication may lead to weight regain.
A balanced view going forward
Generic semaglutide will expand options for people with obesity and metabolic disease, and could ease pressure on health systems. At the same time, cheaper access risks widening cosmetic use, increasing stigma, and raising difficult questions about who should take lifelong medication for weight management. Patients, clinicians and policymakers will need clear criteria, better measures of adiposity than BMI, and public discussion about stigma and equitable coverage.
The coming era of affordable GLP-1s is not just a pharmaceutical shift. It is a cultural one, and managing it will require clinical nuance, ethical clarity and attention to the lived experience of people whose bodies have long been judged by numbers on a scale.
semaglutideozempicweight-lossbody-imagehealth-care
